20‐year trajectories of positive and negative symptoms after the first psychotic episode in patients with schizophrenia spectrum disorder: results from the OPUS study

Abstract

This study aimed to identify the 20‐year trajectories of positive and negative symptoms after the first psychotic episode in a sample of patients with an ICD‐10 diagnosis of schizophrenia spectrum disorder, and to investigate the baseline characteristics and long‐term outcomes associated with these trajectories. A total of 373 participants in the OPUS trial were included in the study. Symptoms were assessed at baseline and after 1, 2, 5, 10 and 20 years using the Scales for the Assessment of Positive and Negative Symptoms. We used latent class growth mixture modelling to identify trajectories, and multinominal regression analyses to investigate predictors of membership to identified trajectories. Five trajectories of positive symptoms were identified: early continuous remission (50.9% of the sample), stable improvement (18.0%), intermittent symptoms (10.2%), relapse with moderate symptoms (11.9%), and continuous severe symptoms (9.1%). Substance use disorder (odds ratio, OR: 2.83, 95% CI: 1.09‐7.38, p=0.033), longer duration of untreated psychosis (OR: 1.02, 95% CI: 1.00‐1.03, p=0.007) and higher level of negative symptoms (OR: 1.60, 95% CI: 1.07‐2.39, p=0.021) were predictors of the relapse with moderate symptoms trajectory, while only longer duration of untreated psychosis (OR: 1.01, 95% CI: 1.00‐1.02, p=0.030) predicted membership to the continuous severe symptoms trajectory. Two trajectories of negative symptoms were identified: symptom remission (51.0%) and continuous symptoms (49.0%). Predictors of the continuous symptoms trajectory were male sex (OR: 3.03, 95% CI: 1.48‐6.02, p=0.002) and longer duration of untreated psychosis (OR: 1.01, 95% CI: 1.00‐1.02, p=0.034). Trajectories displaying continuous positive and negative symptoms were linked to lower neurocognition, as measured by the Brief Assessment of Cognition in Schizophrenia (BACS) (z‐score: –0.78, CI: –1.39 to –0.17, for continuous positive symptoms; z‐score: –0.33, CI: –0.53 to –0.13, for continuous negative symptoms). The same trajectories were also linked to higher use of antipsychotic medication at 20‐year follow‐up (continuous positive symptoms: 78%; continuous negative symptoms: 67%). These findings suggest that the majority of patients with first‐episode schizophrenia spectrum disorder have a trajectory with early stable remission of positive symptoms. Long duration of untreated psychosis and comorbid substance abuse are modifiable predictors of poor trajectories for positive symptoms in these patients. In about half of patients, negative symptoms do not improve over time. These symptoms, in addition to being associated with poor social and neurocognitive functioning, may prevent patients from seeking help.

Cognitive Inflexibility Predicts Negative Symptoms Severity in Patients with First-Episode Psychosis: A 1-Year Follow-Up Study

“…The positive association of DUP with the 1-year PANSS negative score in our study is in agreement with the previous findings discussed below [61]. Advanced synthesis of existing data through a recent umbrella review and random-effects meta-analysis suggests a consistent pattern: longer DUP correlates with more pronounced negative symptoms both at initial presentation and during follow-up [62].…”

Advances in the understanding of the pathophysiology of schizophrenia and bipolar disorder through induced pluripotent stem cell models

“…People presenting with the same diagnosis of either schizophrenia or bipolar disorder show a large heterogeneity in clinical presentation and extreme variability for the biological factors, neurobiological markers, and environmental variables associated with their pathology. 257 , 258 This interindividual variability has hindered research in the field of schizophrenia and bipolar disorder since it has also affected the identification of the pathophysiological mechanisms underpinning their onset.…”

The Role of Lurasidone in Managing Depressive Symptoms in People with Schizophrenia: A Review

“…More recently, studies focusing on the clinical high-risk and ultra-high-risk populations have found that patients with high sensitivity to stress and a tendency to develop negative depressive states are at higher risk of developing full-blown psychotic disorders [ 17 , 18 , 19 ]. In addition, experience sampling studies have found that patients with schizophrenia spectrum disorders exhibit more negative affect in their daily lives, while laboratory studies have shown that these patients have a bias toward judging neutral stimuli as more negative.…”